4.2 Article

Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours

Journal

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.bpg.2012.12.004

Keywords

Neuroendocrine tumour NET; Computed tomography CT; Magnetic resonance imaging MRI; Scintigraphy; SPECT; OctreoScan; Positron emission tomography PET; Ultrasound US; Endoscopic ultrasound EUS; 68Ga; 68Ga-DOTATOC; 11C-5-hydroxytryptophan; FDOPA

Ask authors/readers for more resources

Neuroendocrine tumours (NETS) comprise a heterogeneous group of neoplasms with very varying clinical expression. A functioning NET, for instance in the pancreas, may be very small and yet give rise to severe endocrine symptoms whereas a patient with a small bowel tumour may present with diffuse symptoms and disseminated disease with a palpable bulky liver. Imaging of NETs is therefore challenging and the imaging needs in the various patients are diverse. The basic modalities for NET imaging are computed tomography (CT) or magnetic resonance imaging (MRI) in combination with somatostatin receptor imaging (SMI) by scintigraphy with 111In-labelled octreotide (OctreoScan) or more recently by positron emission tomography (PET) with 68Ga-labelled somatostatin analogues. In this review these various morphological and functional imaging modalities and important methodological aspects are described. Imaging requirements for the various types of NETs are discussed and typical image findings are illustrated. (C) 2013 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available